news
CHMP adopts positive opinion for Lilly’s ixekizumab
26 February 2016 | By Victoria White
Ixekizumab is an IgG4 monoclonal antibody that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor...
List view / Grid view
Psoriasis (PsO)
news
Sandoz acquires rights to biosimilar infliximab in the EEA
12 February 2016 | By Victoria White
Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
news
Cosentyx to achieve blockbuster status
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
news
Investigational Enbrel biosimilar CHS-0214 meets primary endpoints
10 November 2015 | By Victoria White
CHS-0214 met its primary endpoints in a Phase 3 study in patients with moderate-to-severe chronic plaque psoriasis...
news
Janssen reveals the psychological impact of psoriasis
14 October 2015 | By Victoria White
Janssen’s EPIDEPSO study was initiated to better understand the correlation between psychosocial comorbidities and psoriasis...
news
Cosentyx demonstrates sustained efficacy in plaque psoriasis
12 October 2015 | By Victoria White
Cosentyx is the first fully human interleukin-17A (IL-17A) inhibitor approved in Europe and the US to treat adult moderate-to-severe plaque psoriasis...
news
BI 655066 cleared skin better than ustekinumab in psoriasis study
8 October 2015 | By Victoria White
Boehringer Ingelheim has reported new results from a Phase II head-to-head psoriasis study that showed superior efficacy of the company’s biologic compound BI 655066 over ustekinumab...
news
Brodalumab studies demonstrate significant improvements in psoriasis
1 October 2015 | By Victoria White
Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signalling...
news
Ustekinumab gets UK launch for adolescents with psoriasis
14 September 2015 | By Victoria White
A clinical study demonstratement that ustekinumab can improve psoriasis symptoms and lessen its impact on quality of life in young people aged 12 and over...
news
Phase 2b findings demonstrate efficacy of guselkumab in treatment of moderate to severe plaque psoriasis
9 July 2015 | By Victoria White
A trial of has shown up to 86% of patients with psoriasis receiving guselkumab achieved a PGA score of cleared psoriasis or minimal psoriasis at week 16...
news
EC approves Stelara for the treatment of plaque psoriasis in adolescent patients
3 July 2015 | By Victoria White
The EC has approved Janssen’s Stelara for the treatment of moderate-to-severe plaque psoriasis in adolescent patients from the age of 12 years and older...
news
AbbVie presents Phase 3 data demonstrating efficacy and safety of HUMIRA in children and adolescents with severe chronic plaque psoriasis
10 June 2015 | By Victoria White
Results from a pivotal Phase 3 study of HUMIRA demonstrate significant and clinically meaningful efficacy in children and adolescents with plaque psoriasis...
news
New data shows Enstilar provides rapid itch relief for psoriasis patients
10 June 2015 | By Victoria White
New data shows that aerosol foam Enstilar provided rapid itch relief and improvements in itch-related sleep loss for patients suffering from psoriasis...
news
Novartis to present new late-breaking Cosentyx data at AAD 2015 showing significant patient benefit in achieving clear skin
13 March 2015 | By Novartis
Novartis announced that new results for Cosentyx(TM) (secukinumab) in moderate-to-severe plaque psoriasis, including detailed findings from the head-to-head CLEAR study and long-term data from the Phase III program, will be presented as late breaking research at the 73rd Annual Meeting of American Academy of Dermatology...
news
Celgene receives positive CHMP opinion for OTEZLA® (apremilast)
24 November 2014 | By Celgene International Sàrl
Celgene receives positive CHMP opinion for OTEZLA® (apremilast), the first oral PDE4 inhibitor for the treatment of patients with psoriasis and psoriatic arthritis...
